Kazia Therapeutics (NASDAQ: KZIA)

Currency in

Last close As at 04/12/2023

1.32

0.04 (3.13%)

Market capitalisation

22m

Kazia Therapeutics’ lead asset paxalisib (a PI3K inhibitor that can cross the blood brain barrier (BBB), licensed from Genentech) is in a pivotal study for glioblastoma (GBM) and in early-stage studies in childhood brain cancers, DIPG and AT/RT. Phase I EVT801 is an inhibitor of VEGFR3.

Latest Insights

View More

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Adam McCarter

Adam McCarter

Associate Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Iain Ross

    Chairman

  • John Friend

    CEO

  • Karen Krumeich

    CFO

Balance Sheet

Forecast net debt (US$m)

6

Forecast gearing ratio (%)

224

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 7.1 28.2 (77.5)
Relative 3.2 19.1 (78.4)
52 week high/low US$6.0/US$0.5

Financials

Edison Investment Research is terminating coverage on Kazia Therapeutics (KZA). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Jun Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 10.7 (3.1) (3.1) (25.09) N/A N/A
2022A 0.0 (14.9) (14.9) (110.57) N/A N/A
2023E 0.0 (19.0) (19.0) (111.41) N/A N/A
2024E 10.8 (17.2) (17.2) (82.84) N/A N/A

edison tv

Healthcare

EVT801, Kazia’s second programme, and capital markets

edison tv

Healthcare

Paxalisib: Beyond glioblastoma and commercial opportunity

ADR Update

Healthcare

Kazia Therapeutics — Several upcoming catalysts

edison tv

Healthcare

Kazia Therapeutics: Edison Open House Healthcare 2022

edison tv

Healthcare

Kazia Therapeutics – introducing novel asset EVT-801

ADR Update

Healthcare

Kazia Therapeutics — Paxalisib Chinese rights licensed

edison tv

Healthcare

Kazia Therapeutics – Edison Open House interview

ADR Update

Healthcare

Kazia Therapeutics — Cantrixil final Phase I data reported

ADR Update

Healthcare

Kazia Therapeutics — An agile pivot

Update

Healthcare

Kazia Therapeutics — An agile pivot

edison tv

Healthcare

Executive interview – Kazia Therapeutics

ADR Update

Healthcare

Kazia Therapeutics — New indications for GDC-0084

Update

Healthcare

Kazia Therapeutics — New indications for GDC-0084

Outlook

Healthcare

Kazia Therapeutics — GDC-0084 Phase II underway

ADR Outlook

Healthcare

Kazia Therapeutics — GDC-0084 Phase II underway

Update

Healthcare

Novogen — GDC-0084 Phase II on track to commence Q417

ADR Update

Healthcare

Novogen — GDC-0084 Phase II on track to commence Q417

ADR Outlook

Healthcare

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Outlook

Healthcare

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Update

Healthcare

Novogen — Update 31 October 2016

ADR Update

Healthcare

Novogen — Update 11 May 2016

Update

Healthcare

Novogen — Update 9 May 2016